

## REFERENCES:

1. Cancer Australia. Australian Cancer Plan [Internet]. [cited 2026 Jun 1]. Available from: <https://www.canceraustralia.gov.au/australian-cancer-plan>
2. National Rural Health Alliance. Cancer in rural Australia [Internet]. 2022 Jul [cited 2026 Jun 1]. Available from: <https://www.ruralhealth.org.au/wp-content/uploads/2024/05/nrha-cancer-factsheet-july2022.pdf>
3. Zhang L, Lu Y. Follow-up care for patients receiving immune checkpoint inhibitors. *Asia Pac J Oncol Nurs*. 2021;8(6):596–603. doi:10.4103/apjon.apjon-2129
4. Cancer Council NSW. Submission to the inquiry into health outcomes and access to health and hospital services in rural, regional and remote New South Wales [Internet]. 2020 Dec 10 [cited 2026 Jun 1]. Available from: <https://www.cancercouncil.com.au/wp-content/uploads/2021/02/Cancer-Council-NSW-Submission-NSW-Parliamentary-Inquiry-into-Rural-Regional-and-Remote-Health-December-2020.pdf>
5. Crawford-Williams F, Goodwin BC, Chambers SK, Aitken JF, Ford M, Dunn J. Information needs and preferences among rural cancer survivors in Queensland, Australia: a qualitative examination. *Aust N Z J Public Health*. 2022;46(1):81–86. doi:10.1111/1753-6405.13163
6. Otty Z, Brown A, Larkins S, Evans R, Sabesan S. Patient and carer experiences of lung cancer referral pathway in a regional health service: a qualitative study. *Intern Med J*. 2023;53(11):2016–2027. doi:10.1111/imj.16022
7. Kang S, Fletcher J, Htut S, Brown A, Lyle M, Sabesan S, et al. Administration of immune checkpoint inhibitors at rural towns using the teleoncology model of care—a North Queensland perspective. *Aust J Rural Health*. 2023;31(3):540–545. doi:10.1111/ajr.12984
8. Khan OF, Monzon J. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. *Curr Oncol*. 2020;27:S43–S50. doi:10.3747/co.27.5111
9. Kim EJ, Kim YJ, Heo JY, Kim M, Lee S, Seo S, et al. Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study. *Front Oncol*. 2023;13:1295923. doi:10.3389/fonc.2023.1295923.

10. Cook O, Recoche K, McIntyre M, Lee S. The evolving challenges of specialist gynaecological cancer nurse roles: a qualitative study. *J Adv Nurs*. 2021;77(2):910–921. doi:10.1111/jan.14639
11. Lanfear, C., & Harding, S. The effectiveness of nurse-led care in supporting self-management in patients with cancer: A systematic review. *Journal of Clinical Nursing*. 2023; 32(23–24), 7996–8006. <https://doi.org/10.1111/jocn.16895>
12. Reumerman M, Tichelaar J, van Eekeren R, van Puijenbroek EP, Richir MC, van Agtmael MA. The potential of training specialist oncology nurses in real-life reporting of adverse drug reactions. *Eur J Clin Pharmacol*. 2021;77(10):1531–1542. doi:10.1007/s00228-021-03138-5
13. Davies M, Duffield E. Durvalumab immunotherapy: nursing management of immune-related adverse events during the journey of patients with stage III non-small cell lung cancer. *Clin J Oncol Nurs*. 2020;24(3):277–284. doi:10.1188/20.CJON.277-283